1. Scrip
  2. >>Business

Novo Nordisk’s Monlunabant Expectations Dashed By Phase II Data

 
• By Elizabeth Cairns

Mid-stage clinical data show why cannabinoid receptor inverse agonism is an unfavored approach to obesity treatment.    

Novo Nordisk HQ
• Source: Shutterstock

Cannabinoid receptor modulation was always a leftfield approach to obesity, and the Phase IIa data snuck out by Novo Nordisk A/S on 20 September, late in the day for a Danish company, are somewhat limp.

Key Takeaways
  • Novo Nordisk’s oral cannabinoid receptor 1 (CB1) inverse agonist monlunabant has succeeded in a Phase II obesity trial, but the weight loss looks lower than the company’s stated expectations.

The lowest dose of the oral cannabinoid receptor 1 (CB1) inverse agonist monlunabant allowed patients to drop 6.4% of their...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

 
• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

More from Scrip

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By Mandy Jackson

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

In partnership with

Podcast Series: Navigating Regulatory & Market Shifts — CRO Perspectives on Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development